RxDoctor Payments Data

Sirintorn Mann, PA

Physician Assistant · Danville, CANPI 1982608576

Payments from drug & device makers

$1,899in general payments, 2019–2025

Across 70 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$813
  • Dexcom, Inc.$265
  • Radius Health, Inc.$143
  • Abbott$103
  • Boehringer Ingelheim$102
  • Ascendis Pharma Endocrinology Inc$83
  • plus $390 from 8 others

What the payments were for

  • Food & beverage$1,84297%
  • Education$573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,899 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$60,468
Medicare patients
124
Services billed
2,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$129,992
OzempicSemaglutide57$110,901
MounjaroTirzepatide48$64,654
RybelsusSemaglutide24$45,361
TrulicityDulaglutide15$41,445
FarxigaDapagliflozin Propanediol25$24,524
JanuviaSitagliptin Phosphate16$21,086
Tresiba Flextouch U-200Insulin Degludec13$16,962
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$14,471
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$11,411
Humalog Kwikpen U-100Insulin Lispro20$8,795
Nano 2nd Gen Pen NeedlePen Needle, Diabetic73$7,297
Tresiba Flextouch U-100Insulin Degludec11$7,138
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,122
Novolog FlexpenInsulin Aspart22$4,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$813$156,26381 claims
Boehringer IngelheimJardiance$102$129,99293 claims
Lilly USA, LLCMounjaro, Trulicity$80$106,09963 claims
AstraZenecaFarxiga$34$24,52425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Danville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →